|
|
|||
 |
BioPortfolio Bulletin | ||
| www.bioportfolio.com |
http://www.bioportfolio.co.uk/bulletin_52.htm September 7th 2004 | ||
|
| |||
|
Lead Sponsor: |
GENTERIC, INC. Webcast
Auction - Complete
State-of-the-Art Biotechnology Facility with Research and Development,
Vivarium and Plant Support Equipment.
Webcast Auction Wednesday, September 15, 2004 beginning at 9:00 AM (PT).
Bid Live in Alameda, CA or on DoveBid's Website. For more information, visit
our website or call 800-665-1042.
http://www.dovebid.com/Auctions/AuctionDetail.asp?auctionID=2774&referraltag=genteb |
||
|
|
|||
|
In this Week's issue: 1) GENTERIC, INC. Webcast Auction - see above 2) DailyUpdates - the publication tracker for the drug discovery community 3) BIOPHEX - 2004 Conference - Sept 28th to 30th - from post discovery to market 4) BioNews Tracking - over 400 life science industry news stories per day 5) New Dermatology Management Reports: Psoriasis, Melanoma, Acne/Rosacea |
|||
| DailyUpdates by e-mail: the publication tracker for the drug discovery community | |||
DailyUpdates
by LeadDiscovery: the only alert service that flags breaking
journal articles & press releases pre-selected for the R&D community.
Click the topic below for today's publications:
For further information on LeadDiscovery
services go to: http://www.bioportfolio.com/LeadDiscovery/index.htm |
|||
|
|
|||
|
BIOPHEX delivers a unique perspective on the strategic and managerial issues that affect everyone in post-discovery development and manufacturing. The conference, produced by Genetic Engineering News, is targeted to help top-level biopharmaceutical professionals successfully transition their drug from post-discovery to market. For more information open: | ||
|
|
|||
| BIONEWS and BIOWATCH NEWS TRACKING SERVICE | |||
|
BioNews consolidates over 400 life science
/ biotechnology and pharmaceutical news stories each working day.
Track the news using BioPortfolio's
BioWatch News Tracking service.
BioWatch BioNews Tracking: To search go to:
|
|||
| New Dermatology Management Reports: Psoriasis, Melanoma, Acne/Rosacea | |||
|
|
Acne
& Rosacea Therapeutics Over 85% of people worldwide suffer from acne (acne vulgaris) at some point in their lives. In the US alone, over 45 million have acne and 13 million have rosacea, generating demand for prescription strength therapeutics, in addition to popular over-the-counter formulations. Drug classes indicated for both acne and rosacea include anti-infectives, antibiotics, anti-inflammatories. Other classes indicated only for acne are hormone modifiers, keratolytics, and retinoids. Although many treatment options are available, even the most commonly prescribed topical therapeutics, like Adapalene for acne and Metronidazole for rosacea, result in adverse side effects like skin irritations, driving the need for improved treatments with higher efficacy levels and better safety profiles. With the time to market often shorter for dermatological products than for other therapeutic classes, ten emerging acne and rosacea therapies in phase II and III clinical development are expected to launch by 2009. Although the market is crowded by competition from generics and OTC preparations, new drug candidates including hormone therapies, anti-infectives, antibiotics, retinoids, and combination products will provide opportunities for smaller pharmaceuticals companies like Atrix, Cipher, and Connectics to gain market share from dominant players like Sanofi-Aventis, Galderma, and Roche. Number of Pages: 148 pp. Release Date: September 2004 To order: http://www.bioportfolio.com/cgi-bin/acatalog/Navigant_Consulting.html Melanoma TherapeuticsMelanoma is the least common but most deadly of all skin cancers. With over 150,000 new cases of melanoma diagnosed each year worldwide, incidence levels are on the rise, especially in the US, where the fair-skinned and rising Sunbelt populations are at high risk for the disease. Current melanoma treatment classes include chemotherapeutics, such as antineoplastic agents, as well as immunotherapeutics, like immunomodulators and vaccines. However, even the most highly prescribed drugs, such as interferon alpha-2a and dacarbazine, have low efficacy ratings and high toxicity levels. As physicians prescribe more adjuvant therapies to complement surgical procedures, there exists a pressing need for novel treatments. Thirteen emerging therapies, many of them immunomodulators, are expected to enter the market by 2009. With their improved response rates and safety profiles, new drug candidates such as Peginterferon alpha-2b are projected to drive market growth significantly and capture greater market share. Emerging treatments are expected to be used as first line therapies over existing ones, led by vaccines such as M-Vax (Avax Technologies), Oncophage (Antigenics, Inc.), and CANVAXIN (CancerVax) that are already in late-stage clinical trials. Once granted unprecedented FDA approval, vaccines can potentially change the landscape of the melanoma therapeutics market. Number of Pages: 135 pp. Release Date: August 2004To order: http://www.bioportfolio.com/cgi-bin/acatalog/Navigant_Consulting.html Psoriasis TherapeuticsPsoriasis is a chronic, immune-mediated skin disease that affects nearly 14 million people worldwide. In addition to physical and traumatic skin damage, psoriasis also causes psychological damage due to its appearance altering effects. Rather than providing a cure for disease sufferers, current psoriasis therapeutics treat merely disease symptoms with many of these drugs proving ineffective, unsafe, and incredibly costly. Among currently available therapeutics, topical corticosteroids and other topical dermatologics are prescribed as first line therapeutics for mild, moderate, and severe psoriasis, while retinoids, immunomodulators, and biologic immunosuppressives are used on- and off-label for the treatment of severe disease. Emerging therapeutics, such as new biologics and topical immunomodulators, will likely have major impacts on market growth with improved efficacy and safety profiles over existing therapeutics. With eight emerging therapies forecasted to enter the market by 2009, several companies such as Abbott and Amgen are positioned to capture and increase their market share. Number of Pages: 136 pp. Release Date: August 2004 To order: http://www.bioportfolio.com/cgi-bin/acatalog/Navigant_Consulting.html
|
||
|
Contact
us:
To unsubscribe, email: bioportfolio-signoff-request@peach.ease.lsoft.com
WITH NO SUBJECT. The system will automatically remove
your email address from the list based on your email
address. If your email has changed please email peter.barfoot@bioportfolio.com
with a list of your email address and we will manually
unsubscribe for you. Thank you for your understanding.
©2004 BioPortfolio Limited
- http://www.bioportfolio.com and http://www.bioportfolio.co.uk
| |||
|
| |||
